الفهرس 
Multiple SclerosisOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Multiple sclerosis is the most famous and pronounced autoimmune disease attacks the central nervous system thought to develop as a result of inflammation associated with autoimmune attacks on neuronal tissues. One of the characteristics of MS is the engagement of the immune system which is confirmed by the data collected from the experimental allergic encephalomyelitis animal model (EAE). It is like MS in the pathology and the presentation which is characterized by functional deficits that are correlated with immune cell infiltration into the brain and spinal cord. T helper (Th) cells and cytokines play major roles in the development and maintenance of the inflammatory process in multiple sclerosis (MS). Th2 immunity, including IL-4 and IL-10, was ascribed a protective role in MS by counteracting Th1 immunity. IFN-b was the first immuno-modulatory agent approved for the treatment of relapsing– remitting MS (RRMS), now in use also for patients with secondary progressive MS (SPMS) who still experience relapses. GLP-1R agonist exenatide, used for the treatment of type 2 diabetes mellitus, also display neuroprotective properties in multiple models of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, peripheral neuropathy, ischemia, and stroke. The aim of this study is to examine the effect glucagon-like peptide-1 receptor (GLP-1R) agonists on Th2 activity in multiple sclerosis and whether the combination of GLP-1R agonists and interferon β beneficial or not.